论文部分内容阅读
应用新研制的~(99m)Tc—ECD 配套药盒进行初步临床研究,结果表明:制备方法简便,性能稳定,标记率97.20±0.02%,血液清除迅速,T1/2α24.75min,T1/2β11.55h;注药后5min 脑内放射性达7.75% ID,30min 达高峰(7.95% ID),脑内生物半衰期>10h;2h 尿排量57.57% ID,尚可经胆道排泄。SPECT 脑血流断层显像清晰,病灶易辨,对比度高,未发现有不良反应。说明~(99m)Tc—ECD 是目前诊断脑缺血性病变的一种新型脑血流显像剂。
The preliminary clinical study of ~ (99m) Tc-ECD kit was carried out. The results showed that the preparation method was simple and stable with the labeling rate of 97.20 ± 0.02% and rapid blood clearance. T1 / 2α24.75min, T1 / 2β11. 55h. The intracranial radioactivity reached 7.75% ID at 5 min after injection, reaching the peak at 30 min (7.95% ID), the biological half-life in brain was> 10h, and the urinary excretion 57.57% at 2h. SPECT cerebral blood flow tomographic imaging clear, easy to distinguish lesions, high contrast, no adverse reactions were found. Description ~ (99m) Tc-ECD is the diagnosis of cerebral ischemic lesions of a new type of cerebral blood flow imaging agent.